Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Nan Mou"'
Publikováno v:
Cancer Medicine, Vol 13, Iss 4, Pp n/a-n/a (2024)
Abstract Introduction Although anti‐CD19 chimeric antigen receptor (CAR) T cell therapy was approved as a very effective salvage strategy in relapsed/refractory (R/R) B cell lymphoma, the experience in R/R gastrointestinal (GI) lymphoma is still in
Externí odkaz:
https://doaj.org/article/9535177f35744ea48bd4af32d7204110
Autor:
Qi Ai, Fanlu Li, Siyi Zou, Zehui Zhang, Yangbing Jin, Lingxi Jiang, Hao Chen, Xiaxing Deng, Chenghong Peng, Nan Mou, Chenlei Wen, Baiyong Shen, Qian Zhan
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
KRAS mutation is a significant driving factor of tumor, and KRASG12V mutation has the highest incidence in solid tumors such as pancreatic cancer and colorectal cancer. Thus, KRASG12V neoantigen-specific TCR-engineered T cells could be a promising ca
Externí odkaz:
https://doaj.org/article/b4dde58416184cff8635d96bf9bbd609
Publikováno v:
Cell Transplantation, Vol 32 (2023)
Maintaining the efficacy of anti-CD19 chimeric antigen receptor modified (CAR) T-cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) relapse after allogeneic hematopoietic stem cell transplant (allo-HSCT) is an urgent problem. I
Externí odkaz:
https://doaj.org/article/8fc340b8c4a1492abad9e9fb65330678
Autor:
Pu Yao, Xiaowen Wang, Qianmei Wang, Qing Dai, Yu Peng, Qian Yuan, Nan Mou, Shan Lv, Bangbi Weng, Yu Wang, Fengjun Sun
Publikováno v:
Pharmaceutics, Vol 15, Iss 7, p 1827 (2023)
Breast cancer is the most common malignant tumor in women and is a big challenge to clinical treatment due to the high morbidity and mortality. The pH/ROS dual-responsive nanoplatforms may be an effective way to significantly improve the therapeutic
Externí odkaz:
https://doaj.org/article/f96b934e66fb4e639d966e2b975205e0
Autor:
Lin Cheng, Bangbi Weng, Changsheng Jia, Lin Zhang, Bin Hu, Li Deng, Nan Mou, Fengjun Sun, Jing Hu
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: The efferocytosis-related molecules have been considered to be correlated with the resistance to cancer chemotherapy. The aim of this study was to investigate the expression and significance of efferocytosis-related molecules in cancers a
Externí odkaz:
https://doaj.org/article/e61444f2a8894fc99024eab843ec8bc3
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Anti-CD19 chimeric antigen receptor T (CAR-T) therapy has achieved remarkable effects in refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). However, when high tumor bulk occurs, patients tend to early progression after CAR-T therapy. He
Externí odkaz:
https://doaj.org/article/5d88cca8d2e84e7b8401564b5ff765f7
Autor:
Pengjiang Liu, Meijing Liu, Cuicui Lyu, Wenyi Lu, Rui Cui, Jia Wang, Qing Li, Nan Mou, Qi Deng, Donglin Yang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
We studied the acute graft-versus-host disease (GVHD) after humanized anti-CD19-CAR T therapy in relapsed B-acute lymphoblastic leukemia (ALL) patients after allogeneic hematopoietic stem cell transplant (allo-HSCT). Fifteen B-ALL patients were enrol
Externí odkaz:
https://doaj.org/article/a110b4d71ea04efbac9f9d3e2660c20c
Autor:
Sun, Pu Yao, Xiaowen Wang, Qianmei Wang, Qing Dai, Yu Peng, Qian Yuan, Nan Mou, Shan Lv, Bangbi Weng, Yu Wang, Fengjun
Publikováno v:
Pharmaceutics; Volume 15; Issue 7; Pages: 1827
Breast cancer is the most common malignant tumor in women and is a big challenge to clinical treatment due to the high morbidity and mortality. The pH/ROS dual-responsive nanoplatforms may be an effective way to significantly improve the therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::637a06181c14edf4ffb82be558d6fa9d
Autor:
Xiupeng Ye, Xuemei Fan, Rui Cui, Juan Mu, Meijing Liu, Cuicui Lyu, Yeqiong Li, Lan Chen, Jin Zhang, Xin Li, Jia Wang, Nan Mou, Qi Deng
Publikováno v:
Annals of Hematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4d4af83bb530a14b10ae7ee014841f2
https://doi.org/10.1007/s00277-023-05255-w
https://doi.org/10.1007/s00277-023-05255-w
Background: What is the difference in efficacy and side effects of radiotherapy bridging CAR-T therapy versus CAR-T therapy followed by radiotherapy? Patients and methods: Fourteen R/R DLBCL patients received radiotherapy before CAR-T therapy (R-C gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0038a7458c2acabfb765e59559f0a9c4
https://doi.org/10.21203/rs.3.rs-2325739/v1
https://doi.org/10.21203/rs.3.rs-2325739/v1
